Nomura Holdings Inc. Buys 12,050,000 Shares of Bausch Health Cos Inc. $BHC

Key Points

• Nomura Holdings Inc. increased its stake in Bausch Health Companies Inc. by 106.2% in the first quarter, owning approximately 23.4 million shares valued at about $151 million.
• Bausch Health reported earnings of $0.90 per share, missing estimates of $0.97, while the company had revenues of $2.57 billion for the quarter.
• Insider John Paulson significantly boosted his holdings by acquiring over 34 million shares, increasing his stake by 96.35% and pushing his total ownership to approximately $636 million.

Nomura Holdings Inc. grew its stake in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 106.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,395,000 shares of the company's stock after acquiring an additional 12,050,000 shares during the period. Bausch Health Cos comprises approximately 0.3% of Nomura Holdings Inc.'s holdings, making the stock its 25th biggest position. Nomura Holdings Inc. owned 6.46% of Bausch Health Cos worth $151,366,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in BHC. Vanguard Group Inc. boosted its holdings in shares of Bausch Health Cos by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock valued at $76,152,000 after buying an additional 61,621 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Bausch Health Cos by 3.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,113,107 shares of the company's stock valued at $25,089,000 after buying an additional 90,166 shares during the period. Compass Rose Asset Management LP raised its position in shares of Bausch Health Cos by 366.7% during the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company's stock worth $16,926,000 after purchasing an additional 1,650,000 shares during the period. Private Management Group Inc. lifted its holdings in shares of Bausch Health Cos by 13.8% in the 1st quarter. Private Management Group Inc. now owns 1,439,426 shares of the company's stock worth $9,313,000 after purchasing an additional 174,176 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Bausch Health Cos by 4.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,341,999 shares of the company's stock worth $8,700,000 after purchasing an additional 57,963 shares during the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised shares of Bausch Health Cos from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Three equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, Bausch Health Cos currently has an average rating of "Hold" and an average price target of $9.00.

Insider Buying and Selling

In other Bausch Health Cos news, Director John Paulson purchased 34,721,118 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The shares were acquired at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the transaction, the director directly owned 70,755,869 shares in the company, valued at approximately $636,802,821. The trade was a 96.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last 90 days, insiders purchased 44,316,834 shares of company stock worth $369,628,560. 19.97% of the stock is owned by corporate insiders.

Bausch Health Cos Stock Performance

Shares of BHC stock traded down $0.14 during trading on Thursday, reaching $7.22. The company had a trading volume of 1,063,080 shares, compared to its average volume of 2,681,601. The company has a market capitalization of $2.67 billion, a PE ratio of 27.75 and a beta of 0.48. The firm's 50 day simple moving average is $6.80 and its two-hundred day simple moving average is $6.09. The company has a debt-to-equity ratio of 141.90, a current ratio of 1.31 and a quick ratio of 0.98. Bausch Health Cos Inc. has a one year low of $4.25 and a one year high of $9.85.

Bausch Health Cos (NYSE:BHC - Get Free Report) last issued its earnings results on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing analysts' consensus estimates of $0.97 by ($0.07). Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. The firm had revenue of $2.57 billion during the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Bausch Health Cos Inc. will post 4.41 earnings per share for the current year.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.